Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 1 of 9 PageID #: 2683
`Case 1:24-cv-00053-TSK Document17-5 Filed 06/12/24 Page 1of9 PagelD #: 2683
`
`EXHIBIT 3
`EXHIBIT 3
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 2 of 9 PageID #: 2684
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Brett A. Postal
`Kayali, Kathryn; Neil B. McLaughlin; "Mascherin, Terri L."
`Patel, Priyata; Mike Cottler; Shaun Van Horn; laurafairneny@quinnemanuel.com; John R. Labbe; Argall, Arthur;
`M710 Team; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept; WFG-
`aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer; Andrew Robey; Max Gottlieb; QE - Samsung
`Bioepis; skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com;
`SERVICE - Formycon Team; MGB-Amgen-ABP938; ABP938; regeneronpatent@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell; Kaitlyn McKitrick; Eylea Biosimilars; Eylea
`RE: In re aflibercept - May 10 submission m/c
`Tuesday, May 28, 2024 7:35:52 PM
`
`Counsel,
`
`We write to follow up on an item raised by counsel for Samsung Bioepis during the meet and confer
`today.
`
`In the spirit of compromise and given the Court’s Order today limiting Regeneron’s preliminary
`injunction motions to the ’865 patent, Amgen is willing to agree to have the parties serve on Amgen
`redacted, non-confidential versions of the parties’ preliminary and permanent injunction briefing,
`supporting declarations and any other supporting papers, and deposition transcripts of Regeneron
`witnesses limited to papers addressing or relating to the ’865 patent. Amgen would request that
`such documents be served no later than June 5, 2024, and Amgen would reserve its right to seek
`redacted versions of all papers related to Regeneron’s other asserted patents at a later date
`following completion of its preliminary injunction proceeding.
`
`Please let us know by COB tomorrow whether the parties are amenable to this proposal. If not, as
`mentioned in my email of Friday, Amgen intends to file with the Court a motion for expedited access
`to the previously requested judicial records.
`
`Regards,
`Brett
`
`
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com
`Website: www.rothwellfigg.com
`
`The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the
`addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy,
`distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst &
`Manbeck, P.C. immediately at (202) 783-6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any
`attachments.
`
`-----Original Message-----
`From: Kayali, Kathryn <KKayali@wc.com>
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 3 of 9 PageID #: 2685
`
`Sent: Tuesday, May 28, 2024 9:59 AM
`To: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com>; 'Mascherin, Terri L.'
`<TMascherin@jenner.com>; Brett A. Postal <bpostal@rothwellfigg.com>
`Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van
`Horn <vanhorn@fr.com>; laurafairneny@quinnemanuel.com; John R. Labbe
`<jlabbe@marshallip.com>; Argall, Arthur <aargall@wc.com>; M710 Team
`<M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-
`johnson.com; DG-Aflibercept <DG-Aflibercept@netorg8512690.onmicrosoft.com>; WFG-
`aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew
`Robey <arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;
`fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938
`<ABP938@rothwellfigg.com>; regeneronpatent@lists.kellogghansen.com; drpogue@cdkrlaw.com;
`sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com>; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea
`<Eylea@wc.com>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`All:
`
`Regeneron is available at 1PM today to address the proposal regarding sealed filings and Friday’s
`filing. Please circulate a dial in.
`
`Best,
`
`Kat
`From: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>
`Date: Monday, May 27, 2024 at 9:55 PM
`To: 'Mascherin, Terri L.' <TMascherin@jenner.com<mailto:TMascherin@jenner.com>>, Brett A.
`Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>
`Cc: Patel, Priyata <Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>, Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>, Shaun Van Horn
`<vanhorn@fr.com<mailto:vanhorn@fr.com>>, laurafairneny@quinnemanuel.com
`<laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>>, John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>, Argall, Arthur
`<aargall@wc.com<mailto:aargall@wc.com>>, M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>, Jamie.Obrien@steptoe-
`johnson.com <Jamie.Obrien@steptoe-johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com>>,
`Gordon.Copland@steptoe-johnson.com <Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com>>, DG-Aflibercept <DG-
`Aflibercept@netorg8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@netorg8512690.onmicrosoft.com>>, WFG-aflibercept@willkie.com <WFG-
`aflibercept@willkie.com<mailto:WFG-aflibercept@willkie.com>>, mhissam@hfdrlaw.com
`<mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>>, Carl Shaffer
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 4 of 9 PageID #: 2686
`
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>, Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>, Max Gottlieb
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>, QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>,
`skl@schraderlaw.com <skl@schraderlaw.com<mailto:skl@schraderlaw.com>>,
`clt@simmermanlaw.com <clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>>,
`fes@simmermanlaw.com <fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>>,
`trey@simmermanlaw.com <trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>>,
`SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com<mailto:SERVICE-
`Formycon_Team@fr.com>>, MGB-Amgen-ABP938 <MGB-Amgen-
`ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>, ABP938
`<ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>,
`regeneronpatent@lists.kellogghansen.com
`<regeneronpatent@lists.kellogghansen.com<mailto:regeneronpatent@lists.kellogghansen.com>>,
`drpogue@cdkrlaw.com <drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>>,
`sruby@cdkrlaw.com <sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>>, Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>, Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>, Eylea Biosimilars
`<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>>, Eylea
`<Eylea@wc.com<mailto:Eylea@wc.com>>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`
`Counsel,
`
`
`
`Biocon/Mylan are in agreement with the revisions to the sealed filing proposal that were provided
`by Formycon/Celltrion/SB, and see no reason to include past filings in the sealed filing proposal.
`
`
`
`Biocon/Mylan are available to meet and confer during the proposed times.
`
`
`
`Regards,
`
`Neil
`
`
`
`Neil B. McLaughlin Ph.D. | Partner
`
`
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 5 of 9 PageID #: 2687
`
`NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>
`DIRECT | 312.222.7241
`OFFICE | 312.527.2157
`[cid:color-sm_5e876483-4c97-4ab1-9a8e-7f2446702a11.png]<http://www.rmmslegal.com/>
`SIX WEST HUBBARD STREET | CHICAGO IL 60654
`WWW.RMMSLEGAL.COM<http://www.RMMSLEGAL.COM>
`
`
`
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi Siwik LLP, are
`confidential, and may be privileged. If you are not the intended recipient, please notify us
`immediately by replying to this message, and destroy all copies of this message and any
`attachments. Thank you.
`From: Mascherin, Terri L. <TMascherin@jenner.com>
`Sent: Monday, May 27, 2024 5:20 PM
`To: Brett A. Postal <bpostal@rothwellfigg.com>
`Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van
`Horn <vanhorn@fr.com>; laurafairneny@quinnemanuel.com; John R. Labbe
`<jlabbe@marshallip.com>; Neil B. McLaughlin <NMcLaughlin@rmmslegal.com>; Argall, Arthur
`<aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-
`Aflibercept@netorg8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey
`<arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;
`fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938
`<ABP938@rothwellfigg.com>; regeneronpatent@lists.kellogghansen.com; drpogue@cdkrlaw.com;
`sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com>; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea@wc.com
`Subject: Re: In re aflibercept - May 10 submission m/c
`
` I
`
` suggest we address this at the same call, then.
`
`
`Terri
`
`On May 27, 2024, at 4:50 PM, Brett A. Postal
`<bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>> wrote:
`
`External Email - Do Not Click Links or Attachments Unless You Know They Are Safe
`Hi Terri,
`
`Thank you for the email.
`
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 6 of 9 PageID #: 2688
`
`We can be available between 12pm – 2pm ET tomorrow. To the extent that the parties meet and
`confer to discuss the May 31 filing tomorrow, we would propose discussing this issue during the
`same meet and confer.
`
`Best regards,
`Brett
`
`<image001.jpg>
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>
`Website: www.rothwellfigg.com<http://www.rothwellfigg.com/>
`
`The information contained in this electronic message and any attachments to this message are
`intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged
`information. If you are not the addressee, note that any disclosure, copy, distribution or use of the
`contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell,
`Figg, Ernst & Manbeck, P.C. immediately at (202) 783-6040 or email us at
`bpostal@rfem.com<mailto:bpostal@rfem.com>, and destroy all copies of this message and any
`attachments.
`
`From: Mascherin, Terri L. <TMascherin@jenner.com<mailto:TMascherin@jenner.com>>
`Sent: Monday, May 27, 2024 3:55 PM
`To: Brett A. Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>
`Cc: Patel, Priyata <Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>; Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>; Shaun Van Horn
`<vanhorn@fr.com<mailto:vanhorn@fr.com>>;
`laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>; John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>; Neil B. McLaughlin
`<NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>; Argall, Arthur
`<aargall@wc.com<mailto:aargall@wc.com>>; M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>; Jamie.Obrien@steptoe-
`johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com>; Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com>; DG-Aflibercept <DG-
`Aflibercept@netorg8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@netorg8512690.onmicrosoft.com>>; WFG-aflibercept@willkie.com<mailto:WFG-
`aflibercept@willkie.com>; mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>; Carl Shaffer
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>; Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>; Max Gottlieb
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 7 of 9 PageID #: 2689
`
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>;
`skl@schraderlaw.com<mailto:skl@schraderlaw.com>;
`clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>;
`fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>;
`trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>; SERVICE - Formycon Team
`<SERVICE-Formycon_Team@fr.com<mailto:SERVICE-Formycon_Team@fr.com>>; MGB-Amgen-
`ABP938 <MGB-Amgen-ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>;
`ABP938 <ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>;
`regeneronpatent@lists.kellogghansen.com<mailto:regeneronpatent@lists.kellogghansen.com>;
`drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>;
`sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>; Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>; Eylea Biosimilars
`<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>>;
`Eylea@wc.com<mailto:Eylea@wc.com>
`Subject: Re: In re aflibercept - May 10 submission m/c
`
`Brett:
`
`We are happy to meet and confer on this. Please suggest some times that work on your end.
`
`Terri
`
`On May 24, 2024, at 3:22 PM, Brett A. Postal
`<bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>> wrote:
`
`External Email - Do Not Click Links or Attachments Unless You Know They Are Safe
`Dear Terri,
`
`Thank you for providing comments on behalf of Formycon, Celltrion, and Samsung Bioepis.
`
`In view of today’s Court Order setting a preliminary injunction schedule in Amgen’s case, we intend
`to seek documents relating to the other preliminary injunction proceedings on an expedited basis.
`We intend to focus our request on the preliminary injunction motions, briefs, and supporting papers
`(including declarations), and deposition transcripts of Regeneron’s declarants. These documents are
`highly relevant to Amgen’s forthcoming preliminary injunction proceeding.
`
`Most, if not all, of these documents have been filed in the MDL member cases prior to consolidation.
`Based on your comments, we understand that Formycon, Celltrion, and Samsung Bioepis do not
`agree to file or serve redacted copies of these preliminary injunction papers despite acknowledging
`that the public has a right of access to documents filed with the Court. Frankly, we do not
`understand the reluctance to provide Amgen with defendants’ non-confidential invalidity and claim
`construction arguments and Regeneron’s responses to those arguments. We request that you please
`reconsider your refusal to file and/or serve redacted copies of these papers.
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 8 of 9 PageID #: 2690
`
`
`If Formycon, Celltrion, and Samsung do not agree by 1pm ET on May 28, 2024 to file and/or serve
`redacted copies of these papers by June 7, 2024, Amgen intends to move the Court for relief on
`Tuesday, May 28. Amgen also reserves the right to serve subpoenas for these documents on the
`defendants and their counsel.
`
`We can be available today or Tuesday to discuss.
`
`Regards,
`Brett
`
`<image001.jpg>
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>
`Website: www.rothwellfigg.com<http://www.rothwellfigg.com/>
`
`The information contained in this electronic message and any attachments to this message are
`intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged
`information. If you are not the addressee, note that any disclosure, copy, distribution or use of the
`contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell,
`Figg, Ernst & Manbeck, P.C. immediately at (202) 783-6040 or email us at
`bpostal@rfem.com<mailto:bpostal@rfem.com>, and destroy all copies of this message and any
`attachments.
`
`From: Mascherin, Terri L. <TMascherin@jenner.com<mailto:TMascherin@jenner.com>>
`Sent: Thursday, May 23, 2024 4:53 PM
`To: Brett A. Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>; Patel, Priyata
`<Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>; Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>; Shaun Van Horn
`<vanhorn@fr.com<mailto:vanhorn@fr.com>>;
`laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>; John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>; Neil B. McLaughlin
`<NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>; 'Argall, Arthur'
`<aargall@wc.com<mailto:aargall@wc.com>>; M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>; Jamie.Obrien@Steptoe-
`Johnson.com<mailto:Jamie.Obrien@Steptoe-Johnson.com>; Gordon.Copland@Steptoe-
`Johnson.com<mailto:Gordon.Copland@Steptoe-Johnson.com>; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com<mailto:DG-
`
`

`

`Case 1:24-cv-00053-TSK Document 17-5 Filed 06/12/24 Page 9 of 9 PageID #: 2691
`
`Aflibercept@NETORG8512690.onmicrosoft.com>>; WFG-aflibercept@willkie.com<mailto:WFG-
`aflibercept@willkie.com>; mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>; Carl Shaffer
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>; Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>; Max Gottlieb
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>;
`skl@schraderlaw.com<mailto:skl@schraderlaw.com>;
`clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>;
`fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>;
`trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>; SERVICE - Formycon Team
`<SERVICE-Formycon_Team@fr.com<mailto:SERVICE-Formycon_Team@fr.com>>; MGB-Amgen-
`ABP938 <MGB-Amgen-ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>;
`ABP938 <ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>
`Cc:
`REGENERONPATENT@lists.kellogghansen.com<mailto:REGENERONPATENT@lists.kellogghansen.co
`m>; drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>;
`sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>; Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>; Eylea Biosimilars
`<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>>;
`Eylea@wc.com<mailto:Eylea@wc.com>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`Brett, here are comments on the draft that you circulated, on behalf of Formycon, Celltrion and SB.
`At a high level, we addressed the following:
`
`
` 1. If this is being entered in the MDL, it should only apply, at most, to filings since the MDL was
`constituted – not to court filings before that date. Anything before the transfer of the cases to the
`MDL is a matter for each individual case.
` 2. The Order should apply only to documents filed with the court – that is all that is impacted by
`the public’s right of access.
` 3. We thought some of the time periods in your draft were too short, and lengthened them
`slightly.
`
`We are happy to discuss.
`
`Regards,
`Terri
`
`From: Mascherin, Terri L.
`Sent: Wednesday, May 22, 2024 1:59 PM
`To: 'Brett A. Postal' <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>; Patel, Priyata
`<Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>; Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>; Shaun Van Horn
`
`